Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
81.48(c) 81.82(c) 81.35(c) 81.67(c) 81.55(c) Last
1 732 931 1 337 895 1 841 023 1 796 816 4 135 371 Volume
-0.48% +0.42% -0.57% +0.39% -0.15% Change
More quotes
Estimated financial data (e)
Sales 2021 37 256 M 43 679 M 43 679 M
Net income 2021 6 046 M 7 088 M 7 088 M
Net Debt 2021 8 002 M 9 381 M 9 381 M
P/E ratio 2021 17,2x
Yield 2021 4,03%
Sales 2022 39 377 M 46 166 M 46 166 M
Net income 2022 7 170 M 8 406 M 8 406 M
Net Debt 2022 4 226 M 4 955 M 4 955 M
P/E ratio 2022 14,5x
Yield 2022 4,25%
Capitalization 102 B 120 B 120 B
EV / Sales 2021 2,96x
EV / Sales 2022 2,71x
Nbr of Employees 99 412
Free-Float 88,4%
More Financials
Company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular,... 
Sector
Pharmaceuticals
Calendar
09/16 | 08:20amPresentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SANOFI
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16PRESS RELEASE : HMNC Brain Health Initiates Pioneering Precision Therapy Program..
DJ
09/15TRANSLATE BIO : LifeSci Index Partners
AQ
09/14TRANSLATE BIO : Sanofi Completes Translate Bio Buyout
MT
09/14SANOFI : Closes On Acquisition Of Translate Bio
MT
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of..
PU
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of..
AQ
09/13VALNEVA : stock slumps after Britain ends COVID vaccine deal
RE
09/13NH TherAguix annonce l'approbation de son -2-
DJ
09/13NH TherAguix registration document approved by -2-
DJ
09/13NH TherAguix registration document approved by Autorité des Marchés Financier..
DJ
09/13Sanofi completed the acquisition of remaining 95.1% stake in Translate Bio, I..
CI
09/10SANOFI : provides update on Phase 3 study evaluating rilzabrutinib for the treat..
PU
09/09PFIZER : EU Drug Regulator OKs Two New Manufacturing Sites for Pfizer-BioNTech's..
MT
09/09KADMON : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger
MT
More news
News in other languages on SANOFI
09:27aGSK et King's College misent sur l'intelligence artificielle contre le cancer
09/14Les valeurs à suivre mercredi 15 septembre 2021 à la Bourse de Paris -
09/14PNRR : al via lavori Task Force CEOforLIFE
09/14Sanofi conclut l'acquisition de Translate Bio
09/14LES MARCHÉS EN CONTEMPLATION : Emission du 14 septembre 2021
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 03/05
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 81,55 €
Average target price 104,66 €
Spread / Average Target 28,3%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI3.77%120 604
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.19.23%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456